Adagene of Suzhou Raises $28 Million in Series B Funding

Adagene, a Suzhou company developing mono-specific and bi-specific antibodies, announced a $28 million Series B financing led by GP Healthcare Capital. Adagene said it would use the capital to advance several programs into clinical proof of concept, and to support discovery of novel therapies for unmet needs. The company develops its own portfolio of candidates and also collaborates with international biopharmas to discover promising antibodies. More details.... Share this with colleagues: // //